Premium
[O2‐01‐05]: A placebo‐controlled, double‐blind trial of the selective AB‐42 lowering agent, flurizan (MPC‐7869, (R)‐flurbiprofen) in patients with mild to moderate Alzheimer's disease
Author(s) -
Wilcock Gordon K.,
Black Sandra,
Haworth Judy,
Laughlin Mark,
Hendrix Suzanne,
Binger MaryHelen,
Zavitz Kenton,
Swabb Edward,
Hobden Adrian
Publication year - 2005
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2005.06.330
Subject(s) - flurbiprofen , placebo , medicine , clinical trial , disease , pharmacology , pathology , alternative medicine
O2-01-05 A PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF THE SELECTIVE A -42 LOWERING AGENT, FLURIZAN (MPC-7869, (R)FLURBIPROFEN) IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE Gordon K. Wilcock, Sandra Black, Judy Haworth, Mark Laughlin, Suzanne Hendrix, Mary-Helen Binger, Kenton Zavitz, Edward Swabb, Adrian Hobden; University of Bristol, Bristol, United Kingdom; Sunnybrook & Women’s, University of Toronto, ON, Canada; North Bristol NHS Trust, Bristol, United Kingdom; Myriad Pharmaceuticals, Inc., Salt Lake City, UT, USA